EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Newer Outpatient Diabetes Therapies and Technologies

Nevin Kamal, Kristen Lee, Grazia Aleppo

Medical Clinics of North America · 2024

DOI: 10.1016/j.mcna.2024.03.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Clinics of North America, 2024. Verfasst von Nevin Kamal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, Suite …. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New diabetes drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic peptide/GLP-1 RAs have emerged to show hemoglobin A1c (HbA1c) reduction, weight loss, and cardiovascular benefits. Similarly, sodium-glucose cotransporter 2 inhibitors' benefits span from HbA1c decrease to cardiovascular and renoprotective effects. Diabetes technology has expanded to include type 2 diabetes mellitus, with literature supporting its use in T2DM on any insulin regimen. Connected insulin pens and insulin delivery devices have opened new solutions to insulin users and automated insulin delivery systems have become the standard of care therapy for type 1 diabetes mellitus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsDiabetes Mellitus, Type 2HumansDiabetes Mellitus, Type 1InsulinGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsInsulin Infusion SystemsAmbulatory CareGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Automated insulin delivery systemsConnected insulin pensContinuous glucose monitoringGLP-1 receptor agonistsSGLT2 inhibitors

Substanzen

Hypoglycemic AgentsInsulinGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, Suite 530, Chicago, IL, USA.
  • Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, Suite 530, Chicago, IL, USA. Electronic address: aleppo@northwestern.edu.

Zitieren

APA

Kamal, N., Lee, K., & Aleppo, G. (2024). Newer Outpatient Diabetes Therapies and Technologies. Medical Clinics of North America. https://doi.org/10.1016/j.mcna.2024.03.002

Vancouver

Kamal N, Lee K, Aleppo G. Newer Outpatient Diabetes Therapies and Technologies. Medical Clinics of North America. 2024. doi:10.1016/j.mcna.2024.03.002

BibTeX
@article{Kamal2024,
  author = {Kamal, Nevin and Lee, Kristen and Aleppo, Grazia},
  title = {Newer Outpatient Diabetes Therapies and Technologies},
  journal = {Medical Clinics of North America},
  year = {2024},
  doi = {10.1016/j.mcna.2024.03.002}
}
Kostenlos starten →